In an interview with Crain’s Detroit Business, University of Michigan’s Kelly Sexton, associate vice president for research, technology transfer, and innovation partnerships, provided an update on last year’s $130 million investment by Deerfield Management Co. LP to accelerate drugs being developed and brought to market through campus researchers. Sexton, who also serves on Ann Arbor SPARK’s board of directors, said there’s need and room to grow biotechnology research at the university with an eye on commercialization.
In the article, Sexton elaborates on the opportunities for U-M, including a request for proposals from faculty seeking funding, other technology transfer activities that are being pursued, and activity within the university’s existing portfolio of biotechnology spin outs.
To read the full article, click here. Please note that Crain’s Detroit Business requires a subscription to access this content.